The efficacy of pegvisomant in patients with acromegaly resistant to 1st generation somatostatin analogues


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. Prospective analysis of the results of the use of pegvisomant (PEG) in the treatment of patients resistant to secondary therapy with high-dose SA1. Methods. The article presents the results of adding PEG to the treatment of 43 patients (19 men, 24 women) who had previously undergone non-radical transsphenoidal adenomectomy and were resistant to long-term treatment with maximum doses of SA1. All patients were additionally prescribed PEG (Somavert) at a starting dose of 10-15 mg (loading dose - 40-60 mg). During treatment, dynamic monitoring of the insulin-like growth factor 1 (IGF-1) level, IGF-1 index (II), hepatic transaminases, and carbohydrate metabolism was carried out. Biochemical remission of acromegaly was recorded at an II value of <1. Duration of treatment ranged from 3 to 21 months (30 patients >6 months). Results. During treatment with PEG, 57% of patients in the resistant group achieved a stable biochemical remission, which made it possible to reduce the dose, and in some cases stop taking SA1. A direct correlation between the drug titration rate and the initial II level, body mass index and the glycosylated hemoglobin level was revealed. Taking the drug was not accompanied by continued growth of the residual tumor and the development of serious side effects (except for the 1st case). Two clinical cases of the use of PEG are described. Conclusion. Adding a 2nd-line drug, PEG, to the treatment of patients with poorly controlled acromegaly against the background of high-dose SA1 monotherapy provides sufficient biochemical and tumor control with minimal side effects. The use of differentiated treatment regimens will increase the effectiveness of pharmacotherapy and reduce the total therapeutic dose of drugs.

全文:

受限制的访问

作者简介

Evgeny Pronin

Endocrinological Dispensary of the Moscow Healthcare Department

Email: r-wp@mail.ru
Endocrinologist

T. Alekseeva

Endocrinological Dispensary of the Moscow Healthcare Department

M. Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

参考

  1. Lim D.S.T, Freseriu M. Personalized Medical Treatment of Patients With Acromegaly. Rev Endocr Pract. 2022;28(3):321-32. Doi: 10.1016/j. eprac.2021.12.017.
  2. Gadelha M.R., Kasuki L., Lim D.S.T., Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268-32. doi: 10.1210/er.2018-00115.
  3. Lopes M.B.S. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017; 134(4}:521-55.
  4. Akirov A., Asa S.L., Amer L., et al. The Clinicopathological Spectrum of Acromegaly. J Clin Med. 2019;8(11):1962. Doi: 10.3390/ jcm8111962.
  5. Ezzat S., Caspar-Bell G.M., Chik C.L., et al. Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract. 2019;25(2):379-93. doi: 10.2158/EP-2018-0500.
  6. Gadelha M.R., Wildemberg L.E., Kasuki L. The Future of Somatostatin Receptor Ligands in Acromegaly. J Clin Endocrinol Metab. 2022;107(2):297-308. doi: 10.1210/clinem/ dgab726.
  7. Sahakian N., Castinetti F., Brue N., Cuny N. Current and Emerging Medical Therapies in Pituitary Tumors. J Clin Med. 2022;11(2):955. doi: 10.3390/jcm11020955.
  8. Fleseriu M., Biller B.M.K., Freda P.U., et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;22(1):1-13. doi.org/10.1007/s11102-020-01091-7.
  9. Vegenas-Moreno E., Vazquez-Borrego M.C., Dios E., et al. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med. 2018;22(3):1640-49. doi: 10.1111/jcmm. 13440.
  10. Corica G., Ceraudo M., Campana C., et al. Octreotide-Resistant Acromegaly: Challenges and Solutions Ther Clin Risk Manag. 2020;16:379-91. doi: 10.2147/TCRM.S183360.
  11. Asa S.L., Casar-Borota O., Chanson P., et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): An International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017;24:C5-8. doi: 10.1530/ERC-17-0004.
  12. Gomes-Porras M., Cardenas-Salas J., Alvares-Escola C. Somatostatin Analogs in Clinical Practice: A Review.Int J Mol Sci. 2020;21(5):1682. doi: 10.3390/ijms21051682.
  13. Colao A.A.L., Bronstein M.D., Brue T., et al. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III (PAOLA) study. Eur J Endocrinol. 2020;182(6):583. doi: 10.1530/EJE-19-0762.
  14. Bollerslev J., Heck A., Olarescu N.C. Management of endocrine disease: individualised management of acromegaly. Eur J Endocrinol. 2019;181(2):57-71. doi: 10.1530/EJE-19-0124.
  15. Giustina A., Arnaldi G., Bogazzi F., et al. Pegvisomant in Acromegaly: An Update. J Endocrinol Invest. 2017;40(6):577-89.
  16. Fleseriu M., Fuhrer-Sakel D., van der Lely A.J. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY Eur J Endocrinol. 2021;185(4):525-38. doi: 10.1530/EJE-21-0239.
  17. Van der Lely A.J., Bernabeu I., Cap J., et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;162(3):325-33. doi: 10.1530/EJE-10-0867.
  18. Buchfelder M., van der Lely A.J., Biller B.M. Longterm treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol. 2018;179(6):219-27. doi: 10.1530/EJE-18-0616.
  19. Leonart L.P, Tonin FS., Ferreira VL, et al. Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine. 2019;63(1):18-26. doi: 10.1007/s12020- 018-1729-7.
  20. Пронин Е.В., Анциферов М.Б., Алексеева Т.М., Пронин В.С. Опыт использования пэгвисоманта в комбинированном лечении акромегалии. Фарматека. 2020;27(12):62-72. [Pronin E.V., Antsiferov M.B., Alekseeva T.M., Pronin VS. Experience of using pegvisomantin the combined treatment of acromegaly Farmateka. 2020;27(12):62-72. (In Russ.)]. doi: 10.18565/pharmateca.2020.12.62-72.
  21. Brue T., Lindberg A., van der Lely A.J., et al. Diabetes in patients with acromegaly treated with pegvisomant: observations from ACROSTUDY. Endocrine. 2019;63(3):563-72. Doi: 10.1007/ s12020-018-1792-0.
  22. Bianchi A., Valentini F., Iuorio R. M., et al. Longterm treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res. 2013;32:20. doi: 10.1186/17569966-32-20.
  23. Yamaguchi H., Shimatsu A., Okayama A., Sato T. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Endocr J. 2020;67(2):201-10. doi: 10.1507/endocrj.EJ19-0266.
  24. Coopmans E.C., van Meyel S.W.F., van der Lely A.J., Neggers S.J.M.M. The position of combined treatment in acromegaly. Arch Endocrinol Metab. 2020;63(6):646-52. doi: 10.20945/23593997000000195.
  25. Boguszewski C.L., Huayllas M.K.P, Vilar L., et al. Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch Endocrinol Metab. 2012;03:363з25.
  26. Bonert V., Mirocha J., Carmichael J., et al. Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. J Clin Endocrinol Metab. 2020;105(9):dgaa444. doi: 10.1210/clinem/ dgaa444.
  27. Ragonese M., Grottoli S., Maffei P., Alibrandi A., et al. How to Improve Effectiveness of Pegvisomant Treatment in Acromegalic Patients. J Endocrinol Invest. 2015;41(5):575-51. Doi: 10.1007/ s40615-017-0773-0.
  28. Strasburger C.J., Mattsson A., Wilton P., et al. Increasing Frequency of Combination Medical Therapy in the Treatment of Acromegaly With the GH Receptor Antagonist Pegvisomant. Eur J Endocrinol. 2015;175 (4):321-29. doi: 10.1530/EJE-17-0996.
  29. Neggers S.J.M.M., Muhammad A., van der Lely A.J. Pegvisomant treatment in acromegaly. Neuroendocrinol. 2016;103:59-65. doi: 10.1159/000351644.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2022
##common.cookie##